Early Funding Paves The Way For Biomedical Innovations
The Rainin Foundation’s early and ongoing investments in three companies help illustrate the opportunities and challenges in this sector.
Author: Laura Wilson, PhD
Posts by Laura Wilson, PhD
Dr. David Artis Reflects On Advancing Cutting-Edge IBD Research
Rainin Foundation Scientific Advisory Board Member Dr. David Artis’ groundbreaking research has been influential to understanding IBD. In this interview he talks about gut health and disease along with emerging opportunities to support innovation.
Meet Scott Snapper, Scientific Advisory Board Co-Chair
The Kenneth Rainin Foundation is pleased to announce that Scott Snapper, MD, PhD, is the new Co-Chair of our Scientific Advisory Board, joining fellow Co-Chair Bana Jabri, MD, PhD.
Placing Patients At The Heart Of A Technology Mission
The G-Tech Medical team discusses the impact of early funding on their “EKG for the gut,” exciting data emerging from current studies and growing interest from researchers and industry.
Innovators Gain Traction And Recognition
Our Health grantmaking aims to advance game-changing research that has the potential to improve the lives of people with IBD so it’s thrilling when our grantees gain recognition or high-profile journals publish their findings.
IBD Research In The Age Of COVID-19
Two of our grantees illustrate distinct and shared ways that the pandemic has disrupted biomedical research and affected the scientific community.
A Novel Idea Reaches A New Milestone
The Foundation made an early Program Related Investment to support Thetis Pharmaceuticals development of a novel therapy for ulcerative colitis, which just reached a new regulatory milestone.
Discoveries And Perspectives Gain Attention
Prominent journals featured cutting-edge advances by five grantees whose research focuses diagnostics, new therapies and biomarkers of mucosal healing that serve patients directly.
Addressing Racial Equity In Biomedical Research
We’ve begun a journey of inquiry into the role that the Rainin Foundation can play to address racial disparities in the biomedical enterprise.
